View in Other Languages

Phosphagenics Limited

ASX:POH ISIN:AU000000POH7

Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical products.

Phosphagenics' core technology is built around the science and application of phosphorylation, a process where the addition of a phosphate group has been found to enhance the bioavailability, activity and safety of existing pharmaceuticals and nutraceuticals, as well as to assist in the production of drug delivery platforms.

Phosphagenics' shares are listed on the Australian Stock Exchange (POH) and the London Stock Exchange's Alternative Investment Market (PSG). An ADR - Level 1 program was established in the U.S. with The Bank of New York Mellon (PPGNY) for U.S. investors to trade in Phosphagenics' stock on the 'over-the-counter' market. In July 2007, this was upgraded to the International OTCQX, a new premium market tier in the U.S. for international exchange-listed companies, operated by Pink Sheets, LLC.

  

News

Australian Market Report of February 7, 2011: Automotive Technology Group (ASX:ATJ) Announce Most Efficient Supercharger System In The World

🕔2/7/2011 1:30:00 PM 9184

Australian Market Report of February 7, 2011 includes: Automotive Technology Group Limited (ASX:ATJ) announced that the company's Sprintex (R) Supercharger is the world's most efficient automotive supercharger system; Coal study highlights export grade thermal coal potential from Aviva Corporation Limited (ASX:AVA) Mmamantswe project in Botswana; EnviroGold Limited (ASX:EVG) has significantly strengthened its management in Latin America; Phosphagenics Limited (ASX:POH) announced collaboration to develop psoriasis drug in USA.

Read Full Article

Phosphagenics Ltd Announce Successful Transdermal Oxycodone Clinical Trial Results

🕔12/17/2007 12:43:13 PM 4022

Phosphagenics Limited ("Phosphagenics") (ASX: POH)(AIM: PSG)(OTCQX: PPGNY) today announced positive results of its Phase 1 clinical trial that showed its delivery technology, TPM, delivered leading pain-relief drug oxycodone through the skin without causing any disruption or irritation.

Read Full Article
###

67,215 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 7) (Last 30 Days: 33) (Since Published: 7557) 

Company Data

    Fax
  • 03 9605 5999 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Listed
  • 1993/08/09 
  • Homepage
  • www.phosphagenics.com

Social Media